A Series A funding round has brought in $4.6 million for Callidus Biopharma, a development-stage biotech firm specializing in rare-disease drugs. The Pennsylvania-based company plans to use the proceeds mainly to speed up preclinical development of its drug candidates for lysosomal storage disorders, including Pompe and Gaucher diseases. Money also will go toward the launch of the firm's proprietary protein-expression technology.

Related Summaries